Acridine carboxamide

Acridine carboxamide
Identifiers
	IUPAC name N-[2-(Dimethylamino)ethyl]-4-acridinecarboxamide;
CAS Number	89459-25-6;
PubChem CID	107805;
ChemSpider	96954;
UNII	0N3V8R4E13;
CompTox Dashboard (EPA)	DTXSID60237739 ;
Chemical and physical data
Formula	C18H19N3O
Molar mass	293.370 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN(C)CCNC(=O)C1=CC=CC2=CC3=CC=CC=C3N=C21;
	InChI InChI=1S/C18H19N3O/c1-21(2)11-10-19-18(22)15-8-5-7-14-12-13-6-3-4-9-16(13)20-17(14)15/h3-9,12H,10-11H2,1-2H3,(H,19,22); Key:XBGNERSKEKDZDS-UHFFFAOYSA-N;

Acridine carboxamide is a chemotherapy agent that is being studied in the treatment of cancer. It belongs to the family of drugs called topoisomerase inhibitors.^{[citation needed]}

While the agent was well tolerated in Phase II clinical trials, it did not show efficacy when tested against various types of cancers.^[1]^[2]^[3]^[4]

References

^ Dittrich C, Dieras V, Kerbrat P, Punt C, Sorio R, Caponigro F, et al. (August 2003). "Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer". Investigational New Drugs. 21 (3): 347–52. doi:10.1023/A:1025476813365. PMID 14578683. S2CID 19095200.
^ Caponigro F, Dittrich C, Sorensen JB, Schellens JH, Duffaud F, Paz Ares L, et al. (January 2002). "Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer". European Journal of Cancer. 38 (1): 70–4. doi:10.1016/S0959-8049(01)00336-7. PMID 11750842.
^ Twelves C, Campone M, Coudert B, Van den Bent M, de Jonge M, Dittrich C, et al. (May 2002). "Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme". Annals of Oncology. 13 (5): 777–80. doi:10.1093/annonc/mdf121. PMID 12075748.
^ Dittrich C, Coudert B, Paz-Ares L, Caponigro F, Salzberg M, Gamucci T, et al. (February 2003). "Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer". European Journal of Cancer. 39 (3): 330–4. doi:10.1016/S0959-8049(02)00559-2. PMID 12565985.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

[1] Dittrich C, Dieras V, Kerbrat P, Punt C, Sorio R, Caponigro F, et al. (August 2003). "Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer". Investigational New Drugs. 21 (3): 347–52. doi:10.1023/A:1025476813365. PMID 14578683. S2CID 19095200.

[2] Caponigro F, Dittrich C, Sorensen JB, Schellens JH, Duffaud F, Paz Ares L, et al. (January 2002). "Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer". European Journal of Cancer. 38 (1): 70–4. doi:10.1016/S0959-8049(01)00336-7. PMID 11750842.

[3] Twelves C, Campone M, Coudert B, Van den Bent M, de Jonge M, Dittrich C, et al. (May 2002). "Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme". Annals of Oncology. 13 (5): 777–80. doi:10.1093/annonc/mdf121. PMID 12075748.

[4] Dittrich C, Coudert B, Paz-Ares L, Caponigro F, Salzberg M, Gamucci T, et al. (February 2003). "Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer". European Journal of Cancer. 39 (3): 330–4. doi:10.1016/S0959-8049(02)00559-2. PMID 12565985.

[1]

[2]

[3]

[4]

See also

References